Clinical Trial Update: Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating pembrolizumab plus lenalidomide in relapsed Hodgkin and non-Hodgkin lymphoma was terminated with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: NYU Langone Health | Conditions: Relapsed Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-08-14